AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 223 filers reported holding AMICUS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,564 | -3.2% | 1,280 | 0.0% | 0.00% | – |
| Q2 2023 | $16,076 | +13.2% | 1,280 | 0.0% | 0.00% | – |
| Q1 2023 | $14,196 | -9.2% | 1,280 | 0.0% | 0.00% | – |
| Q4 2022 | $15,628 | +1462.8% | 1,280 | +1261.7% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 94 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 94 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 94 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | -94.1% | 94 | -94.4% | 0.00% | – |
| Q1 2021 | $17,000 | -52.8% | 1,673 | +10.6% | 0.00% | – |
| Q4 2020 | $36,000 | +12.5% | 1,513 | -33.4% | 0.00% | – |
| Q3 2020 | $32,000 | +128.6% | 2,272 | +140.2% | 0.00% | – |
| Q2 2020 | $14,000 | +55.6% | 946 | -6.1% | 0.00% | – |
| Q1 2020 | $9,000 | +800.0% | 1,007 | +1298.6% | 0.00% | – |
| Q4 2019 | $1,000 | -99.9% | 72 | -99.9% | 0.00% | -100.0% |
| Q3 2019 | $975,000 | -54.5% | 121,625 | -29.1% | 0.00% | -50.0% |
| Q2 2019 | $2,141,000 | -39.0% | 171,572 | -33.5% | 0.00% | -50.0% |
| Q1 2019 | $3,509,000 | +4842.3% | 258,071 | +4295.7% | 0.00% | – |
| Q3 2018 | $71,000 | -95.2% | 5,871 | -93.8% | 0.00% | -100.0% |
| Q2 2018 | $1,470,000 | -20.2% | 94,093 | -23.1% | 0.00% | -50.0% |
| Q1 2018 | $1,842,000 | -0.4% | 122,422 | -4.7% | 0.00% | 0.0% |
| Q4 2017 | $1,849,000 | -36.3% | 128,498 | -33.3% | 0.00% | -33.3% |
| Q3 2017 | $2,904,000 | +1836.0% | 192,521 | +1191.5% | 0.00% | – |
| Q2 2017 | $150,000 | +24.0% | 14,907 | -11.8% | 0.00% | – |
| Q1 2017 | $121,000 | +44.0% | 16,907 | 0.0% | 0.00% | – |
| Q4 2016 | $84,000 | -4.5% | 16,907 | +42.0% | 0.00% | – |
| Q3 2016 | $88,000 | +63.0% | 11,907 | +20.2% | 0.00% | – |
| Q2 2016 | $54,000 | +5.9% | 9,907 | +65.1% | 0.00% | – |
| Q1 2016 | $51,000 | +50.0% | 6,000 | +71.4% | 0.00% | – |
| Q4 2015 | $34,000 | -51.4% | 3,500 | -30.0% | 0.00% | – |
| Q3 2015 | $70,000 | +66.7% | 5,000 | +66.7% | 0.00% | – |
| Q2 2015 | $42,000 | +250.0% | 3,000 | +50.0% | 0.00% | – |
| Q3 2014 | $12,000 | -55.6% | 2,000 | -75.0% | 0.00% | – |
| Q2 2014 | $27,000 | +42.1% | 8,000 | 0.0% | 0.00% | – |
| Q3 2013 | $19,000 | +171.4% | 8,000 | +166.7% | 0.00% | – |
| Q2 2013 | $7,000 | – | 3,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |